Fed. Circ. Questions Specificity Needed In Oxy IP Invalidation
A Federal Circuit panel expressed frustration with attorneys from both Purdue Pharma LP and generic-drug maker Accord Healthcare Inc. Wednesday as it tried to navigate whether the Delaware district court order...To view the full article, register now.
Already a subscriber? Click here to view full article